2023 World Conference on Lung Cancer (Posters)-EP06.03. Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations

EP06.03. Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations - PDF(Abstract)

Back to course

Pdf Summary

The study presented in this abstract aimed to evaluate the demographic and genomic characteristics of patients with non-small cell lung cancer (NSCLC) who have alterations in the ARID1A gene. ARID1A is a tumor suppressor gene involved in chromatin remodeling and has been linked to better outcomes with immune checkpoint inhibitor therapy. The study included 85 NSCLC patients with ARID1A alterations and 184 NSCLC patients without such alterations.<br /><br />The results showed that patients with ARID1A alterations were more likely to be younger than 65, have squamous histology, and be of Black ethnicity. In comparison, patients without ARID1A alterations were more likely to be never smokers and have a performance status of 0 or 1. There were no significant differences in gender between the two groups. <br /><br />In terms of treatment, a majority of patients with ARID1A alterations received immune checkpoint inhibitors, either as monotherapy or in combination with chemotherapy. Tissue testing showed that these patients had higher expression of PD-L1 and a higher tumor mutational burden (TMB) compared to patients without ARID1A alterations. ARID1A alterations were less frequently associated with EGFR mutations but more frequently associated with HER2 mutations. There were no significant differences in the frequency of other mutations examined.<br /><br />The study concludes that ARID1A alterations may serve as a potential biomarker for immune checkpoint inhibitor efficacy in NSCLC. The findings support the notion that patients with ARID1A alterations have a different mutational landscape and demographic profile compared to those without these alterations. Further analysis of the efficacy of immune checkpoint inhibitors in these patients is needed to determine their potential as a biomarker for treatment response.

Asset Subtitle

Ebaa Al-Obeidi

Meta Tag

Speaker Ebaa Al-Obeidi

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

non-small cell lung cancer

ARID1A gene

genomic characteristics

tumor suppressor gene

chromatin remodeling

immune checkpoint inhibitors

PD-L1 expression

tumor mutational burden

EGFR mutations

biomarker